By Sabela Ojea

PureTech Health PLC said Friday that a product of its founded entity Vor Biopharma Inc. has been granted fast track designation by the U.S. Food and Drug Administration.

The London-listed biotechnology company said Vor Biopharma's VOR33 lead engineered stem cell is now a therapeutic candidate for the treatment of acute myeloid leukemia.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

September 10, 2021 03:17 ET (07:17 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Puretech Health Charts.
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Puretech Health Charts.